Silverback Therapeutics Stock Today
| SPRY Stock | 13.11 1.18 8.26% |
Performance0 of 100
| Odds Of DistressOver 53
|
Silverback Therapeutics is trading at 13.11 as of the 1st of February 2025; that is 8.26 percent decrease since the beginning of the trading day. The stock's open price was 14.29. Silverback Therapeutics has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 2nd of January 2025 and ending today, the 1st of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of December 2020 | Category Healthcare | Classification Health Care |
Silverback Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 97.19 M outstanding shares of which 14.81 M shares are at this time shorted by private and institutional investors with about 10.31 trading days to cover. More on Silverback Therapeutics
Moving together with Silverback Stock
Moving against Silverback Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Silverback Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSilverback Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Silverback Therapeutics' financial leverage. It provides some insight into what part of Silverback Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Silverback Therapeutics (SPRY) is traded on NASDAQ Exchange in USA. It is located in 11682 El Camino Real, San Diego, CA, United States, 92130 and employs 24 people. Silverback Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.39 B. Silverback Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 97.19 M outstanding shares of which 14.81 M shares are at this time shorted by private and institutional investors with about 10.31 trading days to cover.
Silverback Therapeutics generates negative cash flow from operations
Check Silverback Therapeutics Probability Of Bankruptcy
Ownership AllocationSilverback Therapeutics shows a total of 97.19 Million outstanding shares. Over half of Silverback Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Silverback Ownership Details
Silverback Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Woodline Partners Lp | 2024-09-30 | 986 K | |
| Royce & Associates, Lp | 2024-09-30 | 691.5 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 653 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 638.6 K | |
| First Turn Management Llc | 2024-09-30 | 593.3 K | |
| Duquesne Family Office Llc | 2024-09-30 | 536.9 K | |
| Millennium Management Llc | 2024-09-30 | 486.7 K | |
| T. Rowe Price Associates, Inc. | 2024-09-30 | 462.5 K | |
| Northern Trust Corp | 2024-09-30 | 452.4 K | |
| Deerfield Management Co | 2024-09-30 | 11.1 M | |
| Ra Capital Management, Llc | 2024-09-30 | 10.9 M |
Silverback Therapeutics Historical Income Statement
Silverback Stock Against Markets
Silverback Therapeutics Corporate Management
| MD MBA | CoFounder Officer | Profile | |
| Kathleen CPA | Chief Officer | Profile | |
| Alexander Esq | Chief Secretary | Profile | |
| Daniel Relovsky | Senior Marketing | Profile | |
| Eric Karas | Chief Officer | Profile | |
| Justin Chakma | Chief Secretary | Profile | |
| Brian MS | SVP Management | Profile |
Additional Tools for Silverback Stock Analysis
When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.